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To the Editor:
In the general population, it has been shown that higher body-mass index (BMI) is associated with increased von willebrand factor (VWF) and factor VIII (FVIII) levels. 1 A higher BMI is also associated with other procoagulant hemostatic changes, and may therefore protect against bleeding. 1 The association between BMI, VWF and FVIII levels, and bleeding phenotype is unknown in von Willebrand disease (VWD) patients. We hypothesize that higher BMI increases VWF and FVIII levels in patients with VWD, and thereby may ameliorate the bleeding phenotype. Therefore, we investigated the association between BMI, VWF and FVIII levels, and the bleeding phenotype in a large cohort of type 1 and type 2 VWD patients.
We included patients from a nationwide cross-sectional study in VWD patients in the Netherlands, known as the "Willebrand in the Netherlands Study" (WiN study). 2, 3 The inclusion criteria were hemorrhagic symptoms or a family history of VWD, and historically lowest VWF:Ag and/or VWF:
RCo ≤0.30 IU/mL and/or FVIII levels (FVIII:C) ≤0.40 IU/mL (for type 2N VWD Briefly, patients filled in a questionnaire on comorbidities, a self-administered version of the condensed Tosetto bleeding score and bleeding episodes that required hemostatic treatment in the year prior to inclusion. BMI was calcu- We compared continuous variables between two groups using an independent t test, and categorical variables with a chi-square test.
The association between BMI categories and occurrence of bleeding in the year prior to inclusion in the study was adjusted for confounders using logistic regression analysis. Outcomes of logistic regression analysis are reported as odds ratio and 95% confidence interval (CI In the total VWD population, patients with normal weight had fewer bleeding episodes requiring hemostatic treatment in the year Studies evaluating nontraumatic splenectomy in patients with myeloid and lymphoid malignancies reported particularly higher morbidity and mortality rates, ranging between 24%-52% and 2%-18%
respectively. [1] [2] [3] [4] Infectious complications including sepsis have been reported to be significantly more common in patients with malignant indications for splenectomy. 5 The goal of this analysis was to evaluate the risk of postoperative septic events in patients undergoing splenectomy for lymphoid and myeloid malignancies as compared to patients with nonmalignant, benign indications.
Our study was a retrospective cohort study of the prospective 
